162 related articles for article (PubMed ID: 37326942)
1. The Safety, Pharmacokinetics, and Pharmacodynamics of SHR2285, an Oral Small Molecule Factor XIa Inhibitor, in Healthy Chinese Volunteers.
Xu J; Zhao N; Huang J; Li J; Zhao X; Xiang Q; Yang S; Dong Y; Wang H; Li Y; Yang G; Cui Y
Clin Drug Investig; 2023 Jun; 43(6):435-445. PubMed ID: 37326942
[TBL] [Abstract][Full Text] [Related]
2. First-In-Human Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of SHR2285, a Small-Molecule Factor XIa Inhibitor in Healthy Subjects.
Chen R; Guan X; Hu P; Dong Y; Zhu Y; Zhang T; Zou J; Zhang S
Front Pharmacol; 2022; 13():821363. PubMed ID: 35222036
[No Abstract] [Full Text] [Related]
3. SHR2285, the first selectively oral FXIa inhibitor in China: Safety, tolerability, pharmacokinetics and pharmacodynamics combined with aspirin, clopidogrel or ticagrelor.
Ma T; Dong Y; Huang L; Yang Y; Geng Y; Fei F; Xie P; Zhao Y; Lin H; Yang Z; Jin Y; Ju X; Sun R; Li J
Front Pharmacol; 2022; 13():1027627. PubMed ID: 36339534
[No Abstract] [Full Text] [Related]
4. First evaluation of the safety, pharmacokinetics, and pharmacodynamics of BAY 2433334, a small molecule targeting coagulation factor XIa.
Thomas D; Kanefendt F; Schwers S; Unger S; Yassen A; Boxnick S
J Thromb Haemost; 2021 Oct; 19(10):2407-2416. PubMed ID: 34192419
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics, pharmacodynamics and safety of BAY 2433334, a novel activated factor XI inhibitor, in healthy volunteers: A randomized phase 1 multiple-dose study.
Kubitza D; Heckmann M; Distler J; Koechel A; Schwers S; Kanefendt F
Br J Clin Pharmacol; 2022 Jul; 88(7):3447-3462. PubMed ID: 35014061
[TBL] [Abstract][Full Text] [Related]
6. First randomized evaluation of safety, pharmacodynamics, and pharmacokinetics of BAY 1831865, an antibody targeting coagulation factor XI and factor XIa, in healthy men.
Nowotny B; Thomas D; Schwers S; Wiegmann S; Prange W; Yassen A; Boxnick S
J Thromb Haemost; 2022 Jul; 20(7):1684-1695. PubMed ID: 35490404
[TBL] [Abstract][Full Text] [Related]
7. First-in-human study to assess the safety, pharmacokinetics and pharmacodynamics of BMS-962212, a direct, reversible, small molecule factor XIa inhibitor in non-Japanese and Japanese healthy subjects.
Perera V; Luettgen JM; Wang Z; Frost CE; Yones C; Russo C; Lee J; Zhao Y; LaCreta FP; Ma X; Knabb RM; Seiffert D; DeSouza M; Mugnier P; Cirincione B; Ueno T; Frost RJA
Br J Clin Pharmacol; 2018 May; 84(5):876-887. PubMed ID: 29346838
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics, pharmacodynamics, and safety of frunexian in healthy Chinese volunteer adults: A randomized dose-escalation phase I study.
Zhang JY; Ruan ZR; Jiang B; Yang DD; Wang JY; Hu Y; Wang YR; Wang YM; Lin YF; Wang LL; Lou HG
Clin Transl Sci; 2024 Apr; 17(4):e13787. PubMed ID: 38558535
[TBL] [Abstract][Full Text] [Related]
9. ONO-7684 a novel oral FXIa inhibitor: Safety, tolerability, pharmacokinetics and pharmacodynamics in a first-in-human study.
Beale D; Dennison J; Boyce M; Mazzo F; Honda N; Smith P; Bruce M
Br J Clin Pharmacol; 2021 Aug; 87(8):3177-3189. PubMed ID: 33450079
[TBL] [Abstract][Full Text] [Related]
10. A phase 1, randomized study to evaluate safety, tolerability, and pharmacokinetics of GDC-3280, a potential novel anti-fibrotic small molecule, in healthy subjects.
Cheung D; Fong A; Ding HT; Cabanski CR; Wang J; Chen Y; Bush J; Harris JM; Pan L
Pulm Pharmacol Ther; 2021 Aug; 69():102051. PubMed ID: 34166834
[TBL] [Abstract][Full Text] [Related]
11. Safety, pharmacokinetics, and pharmacodynamics of milvexian in healthy Japanese participants.
Perera V; Wang Z; Lubin S; Ueno T; Shiozaki T; Chen W; Xu X; Seiffert D; DeSouza M; Murthy B
Sci Rep; 2022 Mar; 12(1):5165. PubMed ID: 35338177
[TBL] [Abstract][Full Text] [Related]
12. Safety, Tolerability, and Pharmacokinetics of the Monoamine Oxidase B Inhibitor, HEC122505, and its Major Metabolite After Single- and Multiple- Ascending Dose, and Food Effect Study in Healthy Chinese Subjects.
Jin C; Yi C; Chen K; Liang H
Eur J Drug Metab Pharmacokinet; 2024 May; 49(3):331-341. PubMed ID: 38446388
[TBL] [Abstract][Full Text] [Related]
13. Contact Activation Inhibitor and Factor XI Antibody, AB023, Produces Safe, Dose-Dependent Anticoagulation in a Phase 1 First-In-Human Trial.
Lorentz CU; Verbout NG; Wallisch M; Hagen MW; Shatzel JJ; Olson SR; Puy C; Hinds MT; McCarty OJT; Gailani D; Gruber A; Tucker EI
Arterioscler Thromb Vasc Biol; 2019 Apr; 39(4):799-809. PubMed ID: 30700130
[TBL] [Abstract][Full Text] [Related]
14. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects.
Stangier J; Rathgen K; Stähle H; Gansser D; Roth W
Br J Clin Pharmacol; 2007 Sep; 64(3):292-303. PubMed ID: 17506785
[TBL] [Abstract][Full Text] [Related]
15. A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects.
Taylor L; Gidal B; Blakey G; Tayo B; Morrison G
CNS Drugs; 2018 Nov; 32(11):1053-1067. PubMed ID: 30374683
[TBL] [Abstract][Full Text] [Related]
16. First-in-human study to assess the safety, pharmacokinetics, and pharmacodynamics of BMS-986141, a novel, reversible, small-molecule, PAR4 agonist in non-Japanese and Japanese healthy participants.
Merali S; Wang Z; Frost C; Meadows-Shropshire S; Hawthorne D; Yang J; Seiffert D
Platelets; 2023 Dec; 34(1):2222846. PubMed ID: 37394920
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics, pharmacodynamics, and safety of fesomersen, a novel antisense inhibitor of factor XI, in healthy Chinese, Japanese, and Caucasian volunteers.
Liu T; Hashizume K; Krieg E; Chen H; Mukaida Y; Thelen K; Friedrichs F; Willmann S; Schwers S; Solms A; Yu R
Clin Transl Sci; 2024 Apr; 17(4):e13784. PubMed ID: 38563414
[TBL] [Abstract][Full Text] [Related]
18. First-in-Human Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of an Oral Formulation of DS-1040, an Inhibitor of the Activated Form of Thrombin-Activatable Fibrinolysis Inhibitor, in Healthy Subjects.
Zhou J; Limsakun T; Yin O; Warren V; Zamora C; Atiee G; Kochan J; Pav J; Kobayashi F; Vashi V; Dishy V
J Clin Pharmacol; 2019 Dec; 59(12):1669-1677. PubMed ID: 31243790
[TBL] [Abstract][Full Text] [Related]
19. Tolerability and pharmacokinetics of TB-402 in healthy male volunteers.
Verhamme P; Pakola S; Jensen TJ; Berggren K; Sonesson E; Saint-Remy JM; Balchen T; Belmans A; Cahillane G; Stassen JM; Peerlinck K; Glazer S; Jacquemin M
Clin Ther; 2010 Jun; 32(6):1205-20. PubMed ID: 20637972
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects.
Stangier J; Stähle H; Rathgen K; Fuhr R
Clin Pharmacokinet; 2008; 47(1):47-59. PubMed ID: 18076218
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
